Starling Oncology: Jorey buys 1,391 call options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Starling Oncology, Inc. ten-percent owner Chernett Jorey purchased 1,391 STLN $4 call options on November 11, 2026, at a reported price of $0.80 per share. The purchased options relate to 139,100 underlying common shares and expire February 19, 2027; Jorey reported holding 6,391 options after the purchase. Jorey stated that the transaction is subject to Section 16(b), calculated a short-swing profit and intends to disgorge it to Starling Oncology. No Rule 10b5-1 plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Call Option (STLN 19FEB27 $4C) F1 | 1,391 | $0.80 | $1K |
Footnotes (1)
- F1. The reported transaction is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transaction, which the reporting person intends to disgorge to the Issuer.
Key Figures
Key Terms
Call Option technical
exercise price financial
short-swing profit regulatory
Section 16(b) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many STLN call options did Chernett Jorey buy, and what were their terms?
What did Chernett Jorey disclose about Section 16(b)?
AI-generated analysis. How Rhea-AI works. Not financial advice.